Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

phoenix pharma d.o.o. bijeljina - диосмин - film tableta - 600 mg/1 tableta - 1 film tableta sadrži: 600 mg diosmin

Βοσνία - Ερζεγοβίνη - Κροατικά - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

phoenix pharma d.o.o. bijeljina - диосмин - film tableta - 600 mg/1 tableta - 1 film tableta sadrži: 600 mg diosmin

Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"evropa lek pharma" doo podgorica - diosmin - film tableta - 600mg

Μαυροβούνιο - Κροατικά - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"evropa lek pharma" doo podgorica - diosmin - film tableta - 600mg

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

viatris healthcare limited - imikimod - condylomata acuminata; keratosis; keratosis, actinic; carcinoma, basal cell - antibiotici i kemoterapeutici za dermatološku uporabu - imiquimod cream is indicated for the topical treatment of :external genital and perianal warts (condylomata acuminata) in adults. small superficial basal cell carcinomas (sbccs) in adults. clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (aks) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. pogledajte odjeljke 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - idarucizumab - hemoragija - svi ostali terapeutski proizvodi - praxbind je specifičan agent preokret za дабигатрана i navodi u odraslih pacijenata s Этексилат (дабигатран этексилат) pri brzom ukidanju ga антикоагулянтное akcija potrebno je:za hitne operacije/hitne procedure;u opasnim za život ili nekontroliranog krvarenja.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

viatris healthcare limited - imikimod - keratosis; keratosis, actinic - antibiotici i kemoterapeutici za dermatološku uporabu - zyclara indicirana je za topikalno liječenje klinički tipične, ne-očigledni, sobe-hipertrofična, vidljiv ili opipljiv aktinička keratoza cijelo lice ili proćelav vlasišta u odraslih imunokompetentnih osoba kada su druge mogućnosti topikalna liječenje kontraindicirana ili manje prikladno.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

biogen netherlands b.v. - nusinersen natrij - mišićna atrofija, kralješnica - ostali lijekovi protiv živčanog sustava - spinraza je indicirana za liječenje 5q spinalne mišićne atrofije.

Κροατία - Κροατικά - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - atorvastatinkalcij trihidrat - filmom obložena tableta - 10 mg - urbroj: jedna filmom obložena tableta sadrži 10 mg atorvastatina u obliku atorvastatinkalcij trihidrata